Discontinuing Statins for Terminally Ill May Improve QOL

This article originally appeared here.
Share this content:
Discontinuing Statins for Terminally Ill May Improve QOL
Discontinuing Statins for Terminally Ill May Improve QOL

FRIDAY, March 27, 2015 (HealthDay News) -- Discontinuing the use of cholesterol-lowering statins in terminally ill patients may improve their quality of life, according to a new study published online March 23 in JAMA Internal Medicine.

The study included 381 patients, average age 74, who had late-stage cancer or other fatal illnesses and were taking statins. Half the patients stopped taking statins while the other half continued to take the drugs.

Median survival time for all the patients in the study was 219 days. The percentage of patients who died within 60 days was not significantly different between patients who kept taking statins and those who did not. "If the results we report -- improved quality of life, no significant differences in mortality, and modest cost savings -- had been produced by a randomized clinical trial of a new drug in patients with advanced life-limiting illness, the trial would be heralded as a breakthrough and there would be discussion of how to speed access to this new drug," the authors write.

"For patients with shorter life expectancy, greater concern about pill burden, and more comfort-oriented goals of care, physicians may endorse discontinuing statins as a means to reduce the number of medications without apparent harmful effects on survival or quality of life," first author Jean Kutner, M.D., of the University of Colorado School of Medicine in Aurora, and colleagues write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »